Publications
515
Citations
30,993
Est. group size
~3
Recurring co-author estimate
Active years
27
Publishing since 2000
Hossein Borghaei's research focuses on lung cancer, especially non-small cell and small cell lung cancer, with an emphasis on immunotherapy (such as checkpoint inhibitors and bispecific T-cell engagers), targeted therapies, and biomarkers that predict treatment response. His work often involves large multi-site clinical trials examining new drug combinations, molecular characterization of tumors, and patient outcomes such as survival and quality of life.
Publication output was relatively steady (around 28-34 per year) from 2017 to 2022, then rose sharply in 2023 and 2024 before dropping off in 2025-2026, likely reflecting incomplete recent-year indexing.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Mitochondrial ACSS1 links acetate metabolism to pyrimidine biosynthesis in nutrient-stressed B-cell lymphomas
Cancer Letters · 2026
- A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.
Journal of Clinical Oncology · 2026
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Clinical Cancer Research · 2026
- Off-Target-Based Tumor Fraction Estimation from Targeted Sequencing Shows Concordance with Orthogonal Methods Across Advanced Solid Tumors
International Journal of Molecular Sciences · 2026
- Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Cancer · 2025
- Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
Advances in Therapy · 2025
- Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nature Communications · 2025
- Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
Journal of Thoracic Oncology · 2025
- Neoadjuvant Chemo-Immunotherapy for Surgically Resectable Non-Small Cell Lung Cancer: Balancing Promise and Pitfalls
Clinical Lung Cancer · 2025
- Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
Clinical Cancer Research · 2025
- Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met
Journal of Thoracic Oncology · 2025
- Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)
Expert Review of Anticancer Therapy · 2025
- S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent <i>KRAS</i> G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
Journal of Clinical Oncology · 2025
- Abstract 3377: The impact of gender and age on real-world progression-free survival (rwPFS) in patients without a smoking history with NSCLC treated with checkpoint inhibitors
Cancer Research · 2025
- Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Research Square · 2025
- Journal of Clinical Oncology×86
- Journal of Thoracic Oncology×60
- Annals of Oncology×25
- Cancer Research×20
- Lung Cancer×8
- David P. Carbone
Medicine · The Ohio State University
- Gregory A. Otterson
Medicine · The Ohio State University
- Erin M. Bertino
Medicine · The Ohio State University
- Shadia I. Jalal
Medicine · Indiana University
- Tamio Okimoto
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile